ExoFlo
Sponsors
Direct Biologics, LLC
Conditions
ARDSAcute Respiratory Distress SyndromeCOVID-19Covid19Crohn DiseaseCrohn's DiseaseCytokine StormHypoxia
Phase 1
Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease
TerminatedNCT05130983
Start: 2023-01-23End: 2024-12-01Updated: 2025-02-11
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
TerminatedNCT05176366
Start: 2022-12-19End: 2024-12-01Updated: 2025-02-11
Study of ExoFlo for the Treatment of Perianal Fistulas
TerminatedNCT05836883
Start: 2023-08-28End: 2024-12-01Updated: 2025-02-11